Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$173.61 USD

173.61
4,066,881

+1.29 (0.75%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $173.95 +0.34 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 28% (181 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

AbbVie's HCV Combo Favorable in Japanese Phase III Study

AbbVie Inc. (ABBV) announced positive top-line data from a phase III study on its pan-genotypic ribavirin (RBV)-free regimen of glecaprevir/pibrentasvir (G/P) in Japanese patients.

    Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)

    Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar to AbbVie Inc.'s (ABBV) Humira.

      Pfizer's Humira Biosimilar Meets Primary Endpoint in Study

      Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment of patients with rheumatoid arthritis.

        AbbVie's Humira and Imbruvica Drive Performance in 2016

        AbbVie Inc.'s (ABBV) share price is up 5.9% so far this year.

          Roche (RHHBY) Hemophilia A Drug Positive in Phase III

          Roche (RHHBY) announced that the phase III study, HAVEN 1, met its primary endpoint.

            The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, U.S. Bancorp, Baker Hughes and Southwest Airlines

            The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, U.S. Bancorp, Baker Hughes and Southwest Airlines

              AbbVie (ABBV) Submits NDA for Next-Gen HCV Combo in US

              AbbVie Inc. (ABBV) announced that it has submitted a New Drug Application (NDA) to the FDA for its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).

                Sheraz Mian headshot

                Analyst Reports for Union Pacific, AbbVie & U.S. Bancorp

                Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Union Pacific (UNP) and U.S. Bancorp (USB).

                  Roche (RHHBY) to Terminate Pacifica Bioscience Agreement

                  Roche Holding AG (RHHBY) announced that it intends to terminate its agreement with Pacifica Bioscience.

                    Gilead to Pay Merck $2.5B in HCV Patent Dispute, Stock Falls

                    Gilead (GILD) has been ordered to pay $2.5 billion in royalties to Merck (MRK) in the largest patent infringement dispute in the history of the U.S.

                      Roche/AbbVie's Leukemia Drug Venclyxto Gains EU Approval

                      Roche (RHHBY) and AbbVie's (ABBV) Venclyxto has gained EU approval for the treatment of appropriate patients with hard-to-treat chronic lymphocytic leukemia.

                        AbbVie (ABBV) Presents Impressive Imbruvica Data at ASH

                        AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, presented encouraging results on their cancer drug Imbruvica at the annual meeting of the American Society of Hematology.

                          Amgen/Allergan File for EU Approval of Avastin Biosimilar

                          Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.

                            AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.

                            AbbVie Inc. (ABBV) announced that the FDA has granted Orphan Drug Designation to its investigational IL-23 inhibitor, risankizumab (ABBV-066; formerly BI 655066), for the treatment of Crohn's disease in pediatric patients.

                              Momenta/Shire's Humira Biosimilar Meets Study Objective

                              Momenta (MNTA) announced positive data from a phase III study on M923 for the treatment of moderate-to-severe chronic plaque psoriasis.

                                The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay

                                The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay

                                  Sheraz Mian headshot

                                  Top Research Reports for Cisco, Amgen & NextEra Energy

                                  Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Cisco (CSCO) and NextEra Energy (NEE).

                                    Arpita Dutt headshot

                                    Pharma Industry Outlook - November 2016

                                    It's been a rough year for pharma and biotech stocks, with media and political focus on the high price of drugs, mixed performance results, slower-than-expected new product launches and increasing competition.

                                      Mark Vickery headshot

                                      Timeout from Q3 Earnings: GDP +2.9%

                                      With GDP at 2.9% in Q3 (first read), we are seeing a snap-back from below-trend growth earlier in the year.

                                        Sheraz Mian headshot

                                        Stock Research Reports for Amazon, Boeing & MasterCard

                                        Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), MasterCard (MA) and Boeing (BA).

                                          Tracey Ryniec headshot

                                          How Value Investors Can Buy Growth

                                          Value and growth is a magical combination. Here???s how to get it.

                                            Sheraz Mian headshot

                                            Top Research Reports for Morgan Stanely, Union Pacific & AbbVie

                                            Today's must-read reports are for AbbVie (ABBV), Morgan Stanley (MS) and Union Pacific (UNP).

                                              5 Biotech Stocks to Bet on This Earnings Season

                                              The happening biotech sector should be a good bet for investors.

                                                Stock Market News for April 07, 2016

                                                Benchmarks closed in the green on Wednesday following gains in biotech and energy stocks